The V2R selective agonist dDAVP increased CAFs in ccRCC mouse xenograft tumors, while a V2R antagonist significantly reduced CAFs in ccRCC tumors. This evidence concerns the gene AVPR2 and nonpapillary renal cell carcinoma.